2-(3-Methyl-piperidin-1-yl)-benzylamine | 869943-43-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-(3-Methyl-piperidin-1-yl)-benzylamine
• 英文别名: [2-(3-methylpiperidin-1-yl)phenyl]methanamine
• CAS: 869943-43-1
• 化学式: C₁₃H₂₀N₂
• 分子量: 204.315
• InChiKey: GDYYTQZYOAPEDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(3-Methyl-piperidin-1-yl)-benzylamine 、 4-[(4-氯苯基)氨基]-4-氧代丁酸 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以45%的产率得到N¹-(4-chlorophenyl)-N⁴-(2-(3-methylpiperidin-1-yl)benzyl)succinamide
  参考文献：
  名称：

  Design, Synthesis, and Antiviral Activity of Entry Inhibitors That Target the CD4-Binding Site of HIV-1

  摘要：

  The CD4 binding site on HIV-1 gp120 has been validated as a drug target to prevent HIV-1 entry to cells. Previously, we identified two small molecule inhibitors consisting of a 2,2,6,6-tetramethylpiperidine ring linked by an oxalamide to a p-halide-substituted phenyl group, which target this site, specifically, a cavity termed "Phe43 cavity". Here we use synthetic chemistry, functional assessment, and structure-based analysis to explore variants of each region of these inhibitors for improved antiviral properties. Alterations of the phenyl group and of the oxalamide linker indicated that these regions were close to optimal in the original lead compounds. Design of a series of compounds, where the tetramethylpiperidine ring was replaced with new scaffolds, led to improved antiviral activity. These new scaffolds provide insight into the surface chemistry at the entrance of the cavity and offer additional opportunities by which to optimize further these potential-next-generation therapeutics and microbicides against HIV-1.

  DOI：

  10.1021/jm3002247

文献信息

• Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
  申请人：Zhang Xiaojun

  公开号：US20070003539A1

  公开（公告）日：2007-01-04

  The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W 1 , Y, Z, R 7 , R 8 , R 9 , and R 11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供了式(I)或(IV)的新型苯基甘氨酰衍生物：或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药，其中变量W、W1、Y、Z、R7、R8、R9和R11如本文所定义。这些化合物是选择性因子VIIa的抑制剂，可用作药物。
• [EN] ACYLGUANIDINES AS TRYPTOPHAN HYDROXYLASE INHIBITORS<br/>[FR] ACYLGUANIDINES COMME INHIBITEURS DE LA TRYPTOPHAN HYDROXYLASE
  申请人：KAROS PHARMACEUTICALS INC

  公开号：WO2015089137A1

  公开（公告）日：2015-06-18

  The present invention is directed to acylguanidines which are inhibitors of tryptophan hydroxylase (TPH), particularly isoform 1 (TPHl), that are useful in the treatment of diseases or disorders associated with peripheral serotonin including, for example, gastrointestinal, cardiovascular, pulmonary, inflammatory, metabolic, and low bone mass diseases, as well as serotonin syndrome, and cancer.

  本发明涉及酰基胍，它们是色氨酸羟化酶（TPH）的抑制剂，特别是isoform 1（TPHl），在治疗与外周血清素有关的疾病或紊乱方面具有用处，例如胃肠道、心血管、肺部、炎症、代谢和骨量低等疾病，以及血清素综合征和癌症。
• Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors
  作者：Daniel R. Goldberg、Stéphane De Lombaert、Robert Aiello、Patricia Bourassa、Nicole Barucci、Qing Zhang、Vishwas Paralkar、Adam J. Stein、Jim Valentine、William Zavadoski

  DOI：10.1016/j.bmcl.2016.04.057

  日期：2016.6

  An increasing number of diseases have been linked to a dysfunctional peripheral serotonin system. Given that tryptophan hydroxylase 1 (TPH1) is the rate limiting enzyme in the biosynthesis off serotonin, it represents an attractive target to regulate peripheral serotonin. Following up to our first disclosure, we report a new chemotype of TPH1 inhibitors where-by the more common central planar heterocycle has been replaced with an open-chain, acyl guanidine surrogate. Through our work, we found that compounds of this nature provide highly potent TPH1 inhibitors with favorable physicochemical properties that were effective in reducing murine intestinal 5-HT in vivo. Furthermore, we obtained a high resolution (1.90 angstrom) X-ray structure crystal structure of one of these inhibitors (compound 51) that elucidated the active conformation along with revealing a dimeric form of TPH1 for the first time. (C) 2016 Elsevier Ltd. All rights reserved.
• PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1910298A2

  公开（公告）日：2008-04-16
• US7456195B2
  申请人：——

  公开号：US7456195B2

  公开（公告）日：2008-11-25